D.E. Shaw & Co
NBIX icon

D.E. Shaw & Co’s Neurocrine Biosciences NBIX Stock Holding History

D.E. Shaw & Co’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10,000
Closed -$1.23M – 3913
2018
Q3 		$1.23M Hold
10,000
– – ﹤0.01% 2547
2018
Q2 		$982K Buy
+10,000
New +$895K ﹤0.01% 2715

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co's NBIX Position: Q1 2026 in Review

D.E. Shaw & Co opened a new position in Neurocrine Biosciences (NBIX) in Q1 2026: 89,184 shares worth $11.7M. The stake represents 0.01% of the portfolio and ranks #1510 among its holdings. This is a return to the name: D.E. Shaw & Co previously reported a position in NBIX as recently as Q1 2025.

D.E. Shaw & Co first reported a position in NBIX in Q2 2013 and has held it in 45 quarters since. The position peaked at $30.9M in Q4 2022. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • D.E. Shaw & Co held 89,184 shares of Neurocrine Biosciences worth $11.7M as of Q1 2026.
  • Neurocrine Biosciences was a new D.E. Shaw & Co position in Q1 2026.
  • Neurocrine Biosciences made up 0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1510 holding.
  • D.E. Shaw & Co first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 45 quarters since.
  • D.E. Shaw & Co's Neurocrine Biosciences position peaked at $30.9M in Q4 2022.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.